Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries
Authors:
- For The Dpv And Dive Registry InitiativesFIFor The Dpv And Dive Registry Initiatives
- Bettina HartmannBHBettina Hartmann
- Stefanie LanzingerSLStefanie Lanzinger
- Gesine van MarkGMGesine van Mark
- Frank Jürgen WoschFWFrank Jürgen Wosch
- Mesut DurmazMDMesut Durmaz
- Maike PlaumannMPMaike Plaumann
- Stefan SziegoleitSSStefan Sziegoleit
- Jochen SeufertJSJochen Seufert
- Reinhard W. HollRHReinhard W. Holl
- Peter BramlagePBPeter Bramlage
- 30 August 2019
- journal article
- research article
- Published by Springer Nature in Acta Diabetologica
- Vol. 57 (2) , 229-236
Abstract
Aims Our study aimed to analyse treatment strategies after failure of initial metformin mono-therapy in adult patients with type-2 diabetes (T2DM). Methods The DIVE and DPV databases were combined and 16,681 adult patients with T2DM and metformin mono-therapy identified. Patients were analysed depending on whether metformin was continued (MET), or whether it was combined with other oral antidiabetics (OAD), with GLP-1 antagonists (GLP-1) or with basal insulin (BOT/BOT plus). Metabolic control, body weight and hypoglycaemia, micro- and macro-vascular events were compared within 1 year. Results A total of 11,911 (71%) participants continued MET until the end of the observation period, 3334 (20.0%) were intensified using OAD, 579 (3%) started on GLP-1, and 857 (5%) were initiated on BOT/BOTplus. Predictors of OAD and BOT/BOTplus therapy were elevated HbA1c, longer diabetes duration and the presence of micro- and macro-vascular diseases, while GLP-1 therapy was predicted by younger age, female sex, higher body weight and shorter diabetes duration. Micro- and macro-vascular diseases were negative predictors of GLP-1 therapy. Effects on HbA1c were highest in the BOT/BOTplus and OAD group, while GLP-1 treatment had the best effect on body weight. Conclusions BOT/BOTplus and OAD show good HbA1c reduction even in patients with longer diabetes duration and in older patients. GLP-1 therapy is effective concerning weight loss in overweight patients and is more often used in females and patients with shorter diabetes duration. Interestingly, despite several studies showing positive effects on micro- and macro-vascular outcomes, prevalent macro-vascular diseases are no predictors of GLP-1 use.Keywords
Funding Information
- Center for the Study of the American South, University of North Carolina, Chapel Hill
- Sanofi Aventis
- AstraZeneca
- Bayer
- Abbott
This publication has 15 references indexed in Scilit:
- Trend of antihyperglycaemic therapy and glycaemic control in 184,864 adults with type 1 or 2 diabetes between 2002 and 2014: Analysis of real-life data from the DPV registry from Germany and AustriaDiabetes Research and Clinical Practice, 2016
- Impact of body weight on antidiabetic treatment and predictors of weight control under real-world conditions: a 2-year follow-up of DiaRegis cohortActa Diabetologica, 2015
- Effect of Patients’ Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes MellitusJAMA Internal Medicine, 2014
- Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better?Diabetes Care, 2014
- DIabetes Versorgungs-Evaluation (DIVE) - eine nationale Initiative zur Qualitätssicherung in der diabetologischen VersorgungDMW - Deutsche Medizinische Wochenschrift, 2013
- Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysisDiabetologia, 2013
- Patterns of Medication Initiation in Newly Diagnosed Diabetes Mellitus: Quality and Cost ImplicationsThe American Journal of Medicine, 2012
- Improved Metabolic Control in Children and Adolescents With Type 1 DiabetesDiabetes Care, 2011
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005
- A framework for diabetes documentation and quality management in Germany: 10 years of experience with DPVComputer Methods and Programs in Biomedicine, 2002